Company Overview

Krsnaa Diagnostics Limited is an India-based diagnostic services provider, offering services in both radiology and pathology. The Company is primarily engaged in the business of providing diagnostic services across India. Krsnaa Diagnostics Limited is recognized as one of India's largest differentiated diagnostic service providers with a Pan-India presence in Radiology and Pathology. It has established a significant presence through partnerships with government hospitals and operates a substantial number of CT and MRI centers.

The company was originally incorporated as `Krsna Diagnostics Private Limited` in Pune, Maharashtra, on December 22, 2010. The name was changed to `Krsnaa Diagnostics Private Limited` on January 29, 2015. Subsequently, it transitioned to a Public Company, becoming Krsnaa Diagnostics Limited on May 6, 2021.

Krsnaa Diagnostics Ltd. stands as the largest Public-Private Partnership (PPP) player in diagnostic healthcare in India. The company operates through a distinctive PPP model, setting it apart from traditional diagnostic service providers. In this model, Central & State Governments invite established and qualified private diagnostic players to perform diagnostic services (pathology & radiology) under tender-based, pre-approved long-term contracts (5-10 Years).

This business model offers several strategic advantages. It provides a cost-efficient operation, leveraging a hospital partnership model (public & private) to benefit from a captive customer base, reduced marketing expenditure, no need for doctor referrals or commissions, and limited rental expenses. This model ensures a large addressable customer base from Day 1, as a majority of the population is treated at government hospitals. There are zero doctor referral fees for patient acquisition and limited expenses on marketing and promotion. Furthermore, the company incurs no rental costs for space provided by government hospitals and benefits from subsidized utility and electricity rates.

Services and Operations

The Company offers comprehensive radiology and pathology services, including X-Ray, computed tomography (CT) scan, magnetic resonance imaging (MRI), mammography, tele-reporting services, and all types of blood and urine investigations. Its technology assists healthcare professionals in diagnosing and treating medical problems by imaging the interior of the human body.

Krsnaa Diagnostics provides specialized diagnostic imaging (including radiology), pathology/clinical laboratory, and tele-radiology services. Through its extensive network of diagnostic centers, the company offers a wide array of tests, comprising 1,394 radiology tests and 2,544 pathological tests, covering a range of specialties and disciplines.

With operations spanning across 17 states and union territories, the Company manages an expansive network of over 1800 centers. It delivers services through a network of 2,015 centers nationwide, utilizing a hub-and-spoke model.

The company has garnered significant industry recognition. Krsnaa Diagnostics is accredited by the College of American Pathologists (CAP), a prestigious certification making it the sole laboratory in India operating under the PPP model to receive such recognition. The Company also operates India's first NABH accredited tele-radiology reporting hub in Pune.

Financial Performance

The market capitalization of Krsnaa Diagnostics was ₹2,266.58 Crore as of July 13, 2025.

Recent Financial Results

Sales increased by 15.74% to ₹717.16 crore for the year ended March 2025, compared to ₹619.63 crore in the previous year ended March 2024. For the full year, net profit rose by 36.54% to ₹77.61 crore in the year ended March 2025, compared to ₹56.84 crore in the previous year ended March 2024.

For the most recent quarter ended September 2024, the company demonstrated strong performance: Sales rose by 19.87% to ₹186.34 crore in the quarter ended September 2024, against ₹155.45 crore in the previous quarter ended September 2023. Net profit of Krsnaa Diagnostics increased by 86.67% to ₹19.60 crore in the quarter ended September 2024, compared to ₹10.50 crore in the previous quarter ended September 2023.

Key Financial Metrics

* Revenue for FY25: ₹717.16 crore

* Net Profit for FY25: ₹77.61 crore

* Q3 FY2024-25 Performance: Sales of ₹186.34 crore, Net Profit of ₹19.60 crore

* PE Ratio: 32.59

* PB Ratio: 2.86

Market Position and Competitive Advantages

Krsnaa Diagnostics offers tests at significantly competitive rates – radiology tests are priced 45% – 60% lower than market rates, and pathology tests are also 45%-60% lower than market rates. This disruptive pricing strategy is enabled by their PPP model, allowing them to achieve economies of scale while maintaining high-quality standards.

The company is strategically focused on expanding its radiology services, capitalizing on a favorable market environment and a strong win-to-bid ratio in tenders. With plans to enhance its retail presence and integrate digital solutions, Krsnaa aims to improve accessibility and patient engagement, particularly in underserved areas.

Strategic Developments

The company has been actively expanding its presence through new partnerships and strategic investments. Krsnaa Diagnostics has recently secured 4 new PPP and private projects across Maharashtra, Delhi, Rajasthan, and Tripura, which offer strong near-term growth visibility. On July 7, the company received a new Letter of Award (LoA) from the Rajasthan Government to execute a lab services agreement under the Free Diagnostics Initiative.

In a significant strategic move, Krsnaa Diagnostics Ltd., one of India's largest providers of integrated diagnostic services, has announced a strategic investment in Apulki Healthcare Private Limited (Apulki), India's first Public Private Partnership (PPP) dedicated to cancer and cardiac care hospitals. Under this collaboration, Krsnaa will provide a comprehensive suite of integrated diagnostic services at Apulki's facilities, enhancing access to advanced and super-specialized diagnostics.

Future Outlook and Growth Prospects

The company is well-positioned to capitalize on a growing diagnostic market driven by increased government healthcare spending. Strategic expansion in the B2C vertical through forward and backward integration enhances growth potential. A robust business model, strategic investments, and a focus on margin expansion are expected to drive strong earnings prospects in the coming year.

Krsnaa Diagnostics continues to focus on expanding its network while maintaining operational efficiency. While current receivable days present a challenge, management is optimistic about reducing these through improved processes. Overall, the company is well-positioned for sustainable growth, emphasizing quality, affordability, and operational efficiency.

Krsnaa Diagnostics represents a unique investment opportunity in India's healthcare sector, combining the stability of government partnerships with the efficiency of private sector operations. The company's focus on underserved markets, cost-effective service delivery, and strategic expansion positions it favorably for continued growth in India's expanding diagnostic services market.